Quant Mutual Fund increased its holding in Pfizer with a Rs 131 crore purchase. Meanwhile, Pari Washington India Master Fund acquired a 2.02% stake in Amrutanjan Health Care, even as other major funds sold shares amid the company's recent decline in quarterly profit.
Significant bulk deal activity was recorded on August 20, 2026, with institutional investors shifting holdings in pharmaceutical and healthcare stocks. Quant Mutual Fund, led by Sandeep Tandon, furthered its investment in Pfizer by acquiring 2.67 lakh shares. The transaction, valued at Rs 131.25 crore, was executed at Rs 4,899.97 per share. This move follows the fund's previous position, where it held 2.22 percent of the pharmaceutical company as of June 2026.
Amrutanjan Health Care Faces Mixed Investor Action
In a parallel development, Pari Washington India Master Fund purchased 5.83 lakh shares of Amrutanjan Health Care, amounting to a 2.02 percent equity stake. The investment was valued at Rs 29.17 crore, with shares changing hands at Rs 500 per share. While this indicates fresh institutional interest, the stock also saw notable divestments. Envision India Fund offloaded 2.13 lakh shares at Rs 523.58 per share, while DSP Mutual Fund sold 5 lakh shares at approximately Rs 500.01 per share.
The buying interest from Pari Washington comes against the backdrop of a challenging financial quarter for Amrutanjan Health Care. In its latest results for Q1 FY27, the company reported a 47.4 percent year-on-year decline in standalone net profit, which fell to Rs 4.37 crore. The management has highlighted margin pressure and increased operational costs as primary factors weighing on the bottom line.
Strategic Shifts and Investor Monitorables
Amrutanjan is currently undergoing a strategic operational shift as it works to bring production of its 'Comfy' brand of sanitary napkins in-house. The company recently commissioned a new manufacturing facility in Telangana to support this objective. While this transition is intended to improve long-term control over manufacturing, it introduces temporary execution risks and elevated operational costs that contributed to the recent dip in profitability.
Investors are likely to monitor the company's ability to stabilize its profit margins in the coming quarters. The successful utilization of the new facility and the subsequent impact on operational efficiency will be critical factors. For Quant Mutual Fund and the broader pharmaceutical sector, market participants often track product demand, raw material inflation, and regulatory developments, which remain key drivers of stock performance in the healthcare space.